Eloxx Pharmaceuticals annual total assets
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Total Assets Growth & History (ELOX)
Eloxx Pharmaceuticals's total assets was $5.3M for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.3M | $2.3M | +77.08% |
| 2024 | 2024-12-31 | $3.0M | $1.3M | +73.83% |
| 2023 | 2023-12-31 | $1.7M | −$19.4M | −91.90% |
| 2022 | 2022-12-31 | $21.1M | −$24.0M | −53.20% |
| 2021 | 2021-12-31 | $45.1M | $18.7M | +70.48% |
| 2020 | 2020-12-31 | $26.5M | −$32.5M | −55.08% |
| 2019 | 2019-12-31 | $58.9M | $8.2M | +16.23% |
| 2018 | 2018-12-31 | $50.7M | $25.9M | +104.64% |
| 2017 · Dec 31 | 2017-12-31 | $24.8M | $21.7M | +692.33% |
| 2017 · Jun 30 | 2017-06-30 | $5.8M | −$3.4M | −36.64% |
| 2016 · Dec 31 | 2016-12-31 | $3.1M | −$12.5M | −80.01% |
| 2016 · Jun 30 | 2016-06-30 | $9.2M | −$10.3M | −52.80% |
| 2015 · Dec 31 | 2015-12-31 | $15.6M | — | — |
| 2015 · Jun 30 | 2015-06-30 | $19.5M | −$13.8M | −41.36% |
| 2014 | 2014-06-30 | $33.3M | $26.2M | +369.65% |
| 2013 | 2013-06-30 | $7.1M | $142,868 | +2.05% |
| 2012 | 2012-06-30 | $7.0M | −$1.6M | −19.10% |
| 2011 | 2011-06-30 | $8.6M | — | — |
Eloxx Pharmaceuticals quarterly total assets
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.24
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $63.4M | — | — |
| Q1 2026 | 2026-03-31 | $8.5M | — | — |
| Q4 2025 | 2025-12-31 | $5.3M | $2.3M | +77.08% |
| Q4 2024 | 2024-12-31 | $3.0M | $1.3M | +73.83% |
| Q4 2023 | 2023-12-31 | $1.7M | −$19.4M | −91.90% |
| Q3 2023 | 2023-09-30 | $6.0M | −$20.8M | −77.52% |
| Q2 2023 | 2023-06-30 | $6.0M | −$26.9M | −81.81% |
| Q1 2023 | 2023-03-31 | $7.2M | −$36.4M | −83.49% |
| Q4 2022 | 2022-12-31 | $21.1M | −$24.0M | −53.20% |
| Q3 2022 | 2022-09-30 | $26.9M | −$28.5M | −51.47% |
| Q2 2022 | 2022-06-30 | $32.9M | −$27.7M | −45.65% |
| Q1 2022 | 2022-03-31 | $43.6M | $23.3M | +114.17% |
| Q4 2021 | 2021-12-31 | $45.1M | $18.7M | +70.48% |
| Q3 2021 | 2021-09-30 | $55.4M | $22.4M | +68.12% |
| Q2 2021 | 2021-06-30 | $60.6M | $20.7M | +51.82% |
| Q1 2021 | 2021-03-31 | $20.4M | −$26.7M | −56.71% |
| Q4 2020 | 2020-12-31 | $26.5M | −$32.5M | −55.08% |
| Q3 2020 | 2020-09-30 | $32.9M | −$35.1M | −51.60% |
| Q2 2020 | 2020-06-30 | $39.9M | −$39.1M | −49.49% |
| Q1 2020 | 2020-03-31 | $47.0M | −$9.8M | −17.31% |
| Q4 2019 | 2019-12-31 | $58.9M | $8.2M | +16.23% |
| Q3 2019 | 2019-09-30 | $68.1M | $11.5M | +20.38% |
| Q2 2019 | 2019-06-30 | $79.0M | $14.8M | +22.98% |
| Q1 2019 | 2019-03-31 | $56.9M | $37.7M | +197.00% |
| Q4 2018 | 2018-12-31 | $50.7M | $25.9M | +104.64% |
| Q3 2018 | 2018-09-30 | $56.5M | $49.9M | +757.76% |
| Q2 2018 | 2018-06-30 | $64.3M | $58.4M | +999.57% |
| Q1 2018 · Mar 31 | 2018-03-31 | $19.2M | $13.3M | +227.87% |
| Q4 2017 · Dec 31 | 2017-12-31 | $24.8M | $21.7M | +692.33% |
| Q1 2018 · Sep 30 | 2017-09-30 | $6.6M | −$421,573 | −6.01% |
| Q4 2017 · Jun 30 | 2017-06-30 | $5.8M | −$3.4M | −36.64% |
| Q1 2017 · Mar 31 | 2017-03-31 | $5.8M | −$4.7M | −44.68% |
| Q4 2016 · Dec 31 | 2016-12-31 | $3.1M | −$12.5M | −80.01% |
| Q1 2017 · Sep 30 | 2016-09-30 | $7.0M | −$12.4M | −63.93% |
| Q4 2016 · Jun 30 | 2016-06-30 | $9.2M | −$10.3M | −52.80% |
| Q1 2016 · Mar 31 | 2016-03-31 | $10.6M | −$6.4M | −37.59% |
| Q4 2015 · Dec 31 | 2015-12-31 | $15.6M | −$2.9M | −15.68% |
| Q1 2016 · Sep 30 | 2015-09-30 | $19.4M | −$8.7M | −30.91% |
| Q4 2015 · Jun 30 | 2015-06-30 | $19.5M | −$13.8M | −41.36% |
| Q3 2015 | 2015-03-31 | $16.9M | $6.0M | +54.38% |
| Q2 2015 | 2014-12-31 | $18.6M | $7.5M | +67.13% |
| Q1 2015 | 2014-09-30 | $28.1M | $22.3M | +383.89% |
| Q4 2014 | 2014-06-30 | $33.3M | $26.2M | +369.65% |
| Q3 2014 | 2014-03-31 | $11.0M | $4.1M | +59.03% |
| Q2 2014 | 2013-12-31 | $11.1M | $5.6M | +103.18% |
| Q1 2014 | 2013-09-30 | $5.8M | −$445,242 | −7.11% |
| Q4 2013 | 2013-06-30 | $7.1M | $142,868 | +2.05% |
| Q3 2013 | 2013-03-31 | $6.9M | −$1.7M | −20.19% |
| Q2 2013 | 2012-12-31 | $5.5M | −$1.4M | −20.32% |
| Q1 2013 | 2012-09-30 | $6.3M | −$2.0M | −24.32% |
| Q4 2012 | 2012-06-30 | $7.0M | −$1.6M | −19.10% |
| Q3 2012 | 2012-03-31 | $8.6M | — | — |
| Q2 2012 | 2011-12-31 | $6.9M | — | — |
| Q1 2012 | 2011-09-30 | $8.3M | — | — |
| Q4 2011 | 2011-06-30 | $8.6M | — | — |
Eloxx Pharmaceuticals total assets trends
Over the last five fiscal years, Eloxx Pharmaceuticals's total assets decreased from $26.5M to $5.3M, a change of −$21.2M. The latest reported quarter, Q2 2026, shows $63.4M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...